Evers Kathinka
Centre for Research Ethics & Bioethics, Uppsala University, Uppsala Science Park, SE-75185 Uppsala, Sweden.
Dialogues Clin Neurosci. 2009;11(4):427-34. doi: 10.31887/DCNS.2009.11.4/kevers.
Pharmacogenomic developments hold promise for personalized medicine in psychiatry with adjusted therapeutic doses, predictable responses, reduced adverse drug reactions, early diagnosis, and personal health planning. The prospects are exciting, but at the same time, these new techniques stand faced with important scientific, ethical, legal, and social challenges that need to be met in order for the scientific advances to be responsibly applied. This review discusses the ethical balance between challenge and opportunity of personalized medicine in psychiatry under the aspects of adequacy, cost:benefit ratio, and therapeutic equity. It is argued that the promising nature of these therapeutic possibilities makes it all the more important to avoid exaggerating the expectations, and that a sophisticated social infrastructure needs to be developed in order to ensure the realistic and responsible application of personalized medicine in psychiatry.
药物基因组学的发展为精神病学的个性化医疗带来了希望,可实现调整治疗剂量、预测反应、减少药物不良反应、早期诊断以及个人健康规划。前景令人振奋,但与此同时,这些新技术面临着重要的科学、伦理、法律和社会挑战,为了科学进步能够得到负责任的应用,必须应对这些挑战。本综述从充分性、成本效益比和治疗公平性等方面讨论了精神病学个性化医疗中挑战与机遇之间的伦理平衡。有人认为,这些治疗可能性的前景使得避免夸大期望变得更加重要,并且需要建立完善的社会基础设施,以确保个性化医疗在精神病学中得到切实可行且负责任的应用。